Search Results | DrugBank Online

Displaying drugs 7176 - 7200 of 7794 in total

Mibenratide

Mibenratide is under investigation in clinical trial NCT01798745 (A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies).

Investigational

Matched Iupac: … 2,5,8,11,14,17,20,23,26,29,32,35,38,41,47,50,53,56-octadecaazatricyclo[35.20.4.0^{43,47}]henhexacontan-13-yl]propanoic acid …

4-{(Z)-[2-[3-(Methylsulfanyl)Propanoyl]-5-Oxo-1-(2-Oxoethyl)-1,5-Dihydro-4h-Imidazol-4-Ylidene]Methyl}Benzenolate

Experimental

1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole

Experimental

(3S)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide

Experimental

N-(4-CHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE

Experimental

Sulfaethoxypyridazine

Vet approved

Sulfabromomethazine

Vet approved

PAC-1

PAC-1 has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers, among others.

Investigational

Sulfamethoxypyridazine

Experimental

PLX-4720

Experimental

T-900607

T900607 has been used in trials studying the treatment of Liver Cancer and Gastric Cancer.

Investigational

Aranidipine

Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity. It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.

Experimental